Research programme: DNA repair enzyme inhibitors - KuDOS
Alternative Names: 1,3-dipropyl-7-methylxanthine; DNA repair enzyme inhibitors research programme - KuDOS; DPMX; KU 55933; KU-0060648; KU-0063794Latest Information Update: 10 May 2026
At a glance
- Originator KuDOS Pharmaceuticals
- Developer KuDOS Pharmaceuticals; Lakefront Biotherapeutics
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA repair enzyme inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 May 2026 Galapagos NV is now called Lakefront Biotherapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 06 Apr 2011 Pharmacodynamics data from preclinical trials in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR-2011)